Heinz Läubli

Prof. Dr. med.
Heinz Läubli, PhD

Position(s)
Leading Physician Medical Oncology
Project Leader Cancer Immunology

Institution
University Hospital Basel

Phone +41 61 556 52 12

Email

 

Research Focus

Oncology & Hematology

Area of Research

Definition of new target molecules and therapies for the treatment of solid tumors, in particular immunomodulatory therapies; analysis of primary tumor material from patients under immunotherapy; description and manipulation of sugar chains in the tumor; development of cellular therapies such as adoptive T cell transfer for the treatment of tumors and translation into phase I/II studies.


Approved Research Projects

  • Ono Research Grant, 2022
  • Innovation Focus Cell Therapy (Co-Applicant), University Hospital, 2021-2026
  • Cancer Research Switzerland, (KFS-5239-02-2021R), 2021-2024
  • Innosuisse grant (42408.1 IP-LS), 2020-2022
  • SNSF Project Grant, (310030_184720/1), 2019-2022
  • Swiss Cancer Research, Treatment of relapsed glioblastoma patients with targeted immunoliposomes, 2017-2019
  • Research Grant, Krebsliga Beider Basel, 2017

Collaborations

National Collaborations

  • Prof. George Coukos, CHUV, Cell Therapies
  • Prof. Markus Jörger, KS St.Gallen, Phase 1 Therapies
  • Prof. Christoph Mamot, KS Aarau, Glioblastom trials
  • Prof. Stephan von Gunten, Bern, Glycosylation in Cancer
  • Prof. Thierry Hennet, Uni ZH, Glycosylation/Enzymes

International Collaborations

  • Prof. Carolyn Bertozzi, Stanford University, CA, USA, Glycan-based therapies
  • Prof. Thomas Boltije, Radboud University, Netherlands, Inhibitors of glycosylation
  • Prof. Ajit Varki, UCSD, CA, USA, Sialic acids and glycans
  • Prof. John Haanen, NKI, Amsterdam, Netherlands, TIL Therapy
  • Prof. Lukas Flatz, Tübingen, Germany, Immunotherapy
  • Prof. Celso Reis, Porto, Portugal, Immunotherapy and Glycans
  • Dr. Oliver Pearce, Barts Cancer Institute, London, UK, Glycans

Ongoing Research Projects

  • Cell Therapies for solid tumors (TIL project, CAR T cell project targeting FAP, using IL-10 to improve CAR T cell therapy, undisclosed new CAR)
  • New IL-2 variants for TIL therapy (together with Anaveon)
  • CAR T cell therapy for Glioblastoma treatment
  • Siglec, sialoglycan targeting (basic and translational research projects)
  • Glycan-targeting for cancer immunotherapy

Research Team

Dr. Natalia Rodrigues Mantuano

Study Nurse

Phone +41 61 265 23 55
Email

Helen Thut 

Research Fellow

Phone +41 61 328 55 82
Email

Andreas Zingg 

Research Fellow

Phone +41 61 265 23 55
Email

Dr. David König 

Research Fellow

Phone +41 61 328 70 74
Email

Reto Ritschard 

Research Fellow

Phone +41 61 328 47 54
Email

Jessica Häusel

Research Fellow

Phone +41 61 328 47 55
Email

Ronja Wieboldt 

Research Fellow

Phone -
Email

Michael Sandholzer 

Research Fellow

Phone +41 61 265 23 55
Email